InspireMD Q1 Revenue Soars 122% to $3.4M, EPS Beats Estimates
InspireMD posted Q1 EPS of -$0.16, beating estimates of -$0.19 and improving from -$0.22 a year ago. Revenue rose 122% year-over-year to $3.4 million, exceeding projections by over 25%, while the company holds a negative P/E of -2.07 and awaits new FDA trial approvals expected later in 2026.
1. Q1 Earnings Beat
InspireMD reported earnings per share of -$0.16 in Q1, outperforming the -$0.19 estimate and improving from a -$0.22 loss in the same quarter last year.
2. Revenue Growth
First-quarter revenue reached $3.4 million, exceeding the $2.7 million projection by over 25% and representing a 122% increase year-over-year, driven by sales of CGuard Prime and original CGuard devices.
3. Profitability and Valuation
The company remains unprofitable with a trailing P/E ratio of -2.07 and an earnings yield of -48.36%, alongside a price-to-sales ratio of 5.06 reflecting its current valuation against revenue.
4. Clinical Trials Outlook
InspireMD secured FDA approval to start a new clinical trial and anticipates additional product approvals later in 2026, potentially expanding its addressable market in neurovascular care.